DexCom Company Leadership

DXCM Stock  USD 85.12  1.09  1.30%   
About 75% of DexCom's corporate insiders are selling. The analysis of insiders' sentiment of trading DexCom Inc stock suggests that many insiders are alarmed at this time. DexCom employs about 10.2 K people. The company is managed by 21 executives with a total tenure of roughly 29 years, averaging almost 1.0 years of service per executive, having 485.71 employees per reported executive.
Kevin Sayer  CEO
CEO and President and Director
Andrew Balo  President
Senior Vice President - Clinical and Regulatory Affairs

Insider Sentiment 25

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-07-05Michael T. McCaulAcquired @ 82.73
2025-06-27Michael T. McCaulDisposed @ 86.33
2025-06-26Sadie SternDisposed 1466 @ 85.06View
2025-06-16Michael T. McCaulDisposed @ 83
2025-06-13Nicholas AugustinosDisposed 2618 @ 81.69View
2025-05-28Ro KhannaAcquired @ 86.98
2025-05-27Sadie SternDisposed 6184 @ 85.11View
2025-05-23Michael Jon BrownDisposed 10000 @ 84.28View
2025-05-15Robert Bresnahan, Jr.Acquired @ 85.67
2025-05-12Jefferson ShreveDisposed @ 85.05
2025-05-08Jefferson ShreveAcquired @ 85.29
2025-04-23Ro KhannaDisposed @ 67.2
2025-04-08Robert Bresnahan, Jr.Disposed @ 60.69
2025-04-07Jefferson ShreveDisposed @ 61.63
2025-03-17Bridgette P HellerDisposed 352 @ 70.33View
2025-03-12Kevin R SayerDisposed 32498 @ 70.38View
Monitoring DexCom's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of DexCom's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of DexCom Inc. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe DexCom's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

DexCom's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with DexCom's future performance. Based on our forecasts, it is anticipated that DexCom will maintain a workforce of about 10200 employees by August 2025.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

DexCom's latest congressional trading

Congressional trading in companies like DexCom Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in DexCom by those in governmental positions are based on the same information available to the general public.
2025-07-09Representative Michael McCaulAcquired $15K to $50KVerify
2025-06-10Representative Rob BresnahanAcquired Under $15KVerify
2025-05-15Representative Michael McCaulAcquired $50K to $100KVerify
2025-05-09Representative Jefferson ShreveAcquired $15K to $50KVerify
2025-04-29Representative Rob BresnahanAcquired Under $15KVerify
2025-04-18Representative Michael McCaulAcquired $15K to $50KVerify
2025-03-28Representative Rob BresnahanAcquired Under $15KVerify
2020-04-16Senator Tina SmithAcquired $250K to $500KVerify
2020-04-15Senator Tina SmithAcquired $250K to $500KVerify
2018-07-15Representative Bradley S SchneiderAcquired $100K to $250KVerify

DexCom Management Team Effectiveness

The company has return on total asset (ROA) of 0.0598 % which means that it generated a profit of $0.0598 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2372 %, meaning that it created $0.2372 on every $100 dollars invested by stockholders. DexCom's management efficiency ratios could be used to measure how well DexCom manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of July 2025, Return On Tangible Assets is likely to grow to 0.1. Also, Return On Capital Employed is likely to grow to 0.18. At this time, DexCom's Net Tangible Assets are very stable compared to the past year. As of the 23rd of July 2025, Intangible Assets is likely to grow to about 108.6 M, while Asset Turnover is likely to drop 0.56.
As of the 23rd of July 2025, Net Income Applicable To Common Shares is likely to grow to about 412 M, while Common Stock Shares Outstanding is likely to drop about 254.7 M.

DexCom Workforce Comparison

DexCom Inc is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 249,534. DexCom holds roughly 10,200 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.13 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13.

DexCom Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DexCom insiders, such as employees or executives, is commonly permitted as long as it does not rely on DexCom's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, DexCom insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-06-01
1.2308
16
13
 127,240 
 43,257 
2025-03-01
1.0714
15
14
 403,888 
 131,462 
2024-06-01
0.6957
16
23
 44,814 
 85,787 
2024-03-01
0.3667
11
30
 292,181 
 218,471 
2023-09-01
0.1538
2
13
 5,552 
 16,127 
2023-06-01
0.6296
17
27
 58,760 
 106,231 
2023-03-01
0.2692
14
52
 407,732 
 328,234 
2022-12-01
0.1667
1
6
 31,449 
 29,425 
2022-09-01
0.5
2
4
 5,599 
 3,553 
2022-06-01
1.4167
17
12
 16,534 
 9,271 
2022-03-01
0.2542
15
59
 123,407 
 65,191 
2021-12-01
0.0845
6
71
 15,042 
 32,436 
2021-09-01
0.0208
2
96
 2,885 
 75,435 
2021-06-01
0.3864
17
44
 32,980 
 96,591 
2021-03-01
0.1857
13
70
 147,055 
 151,265 
2020-12-01
0.0704
5
71
 38,706 
 59,604 
2020-09-01
0.0187
2
107
 8,127 
 153,139 
2020-06-01
0.1579
15
95
 26,205 
 94,536 
2020-03-01
0.0897
14
156
 149,650 
 226,296 
2019-12-01
0.0189
1
53
 18,377 
 90,214 
2019-09-01
0.0282
2
71
 7,497 
 153,443 
2019-06-01
0.28
14
50
 45,617 
 98,582 
2019-03-01
0.2121
14
66
 210,700 
 194,083 
2018-12-01
0.0526
3
57
 33,484 
 125,961 
2018-09-01
0.0824
7
85
 96,115 
 339,118 
2018-06-01
0.8148
22
27
 161,146 
 320,577 
2018-03-01
0.3667
11
30
 427,238 
 124,397 
2017-12-01
0.2
2
10
 35,000 
 41,040 
2017-09-01
0.1071
3
28
 74,524 
 104,949 
2017-06-01
0.55
11
20
 76,221 
 115,583 
2017-03-01
0.3429
36
105
 502,692 
 658,670 
2016-12-01
0.1667
4
24
 21,000 
 111,964 
2016-09-01
0.1667
15
90
 180,335 
 821,915 
2016-06-01
0.359
14
39
 231,746 
 437,942 
2016-03-01
0.3111
14
45
 407,771 
 312,677 
2015-12-01
0.3768
26
69
 234,001 
 577,077 
2015-09-01
0.2537
17
67
 306,828 
 834,921 
2015-06-01
0.4141
41
99
 390,988 
 1,036,088 
2015-03-01
0.4568
37
81
 542,727 
 553,180 
2014-12-01
0.473
35
74
 510,630 
 1,051,923 
2014-09-01
0.434
46
106
 545,017 
 1,164,853 
2014-06-01
0.5882
30
51
 251,994 
 471,232 
2014-03-01
0.5052
49
97
 1,230,047 
 1,362,007 
2013-12-01
0.4
20
50
 258,376 
 643,041 
2013-06-01
0.4615
6
13
 97,339 
 171,353 
2013-03-01
0.5333
8
15
 584,850 
 148,960 
2012-06-01
0.6667
4
6
 88,826 
 69,741 
2012-03-01
0.7
7
10
 535,684 
 51,654 
2010-06-01
14.0
28
2
 115,680 
 6,606 
2010-03-01
13.0
13
1
 474,250 
 10,000 
2009-12-01
18.0
18
1
 93,245 
 3,861 
2009-06-01
5.0
20
4
 273,721 
 70,000 
2008-09-01
1.0
4
4
 160,000 
 27,500 
2007-12-01
7.0
7
1
 189,937 
 24,427 
2007-09-01
3.6667
22
6
 155,000 
 39,500 
2007-06-01
13.0
13
1
 1,166,221 
 26,255 
2006-06-01
1.0
20
20
 341,388 
 2,921,328 
2006-03-01
0.2889
13
45
 126,577 
 99,972 
2005-12-01
0.375
18
48
 281,858 
 2,669,646 
2005-06-01
0.9348
43
46
 19,114,425 
 17,306,408 

DexCom Notable Stakeholders

A DexCom stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as DexCom often face trade-offs trying to please all of them. DexCom's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting DexCom's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Kevin SayerCEO and President and DirectorProfile
Andrew BaloSenior Vice President - Clinical and Regulatory AffairsProfile
Jereme CPACFO VPProfile
Jacob LeachExecutive COOProfile
Girish NaganathanExecutive CTOProfile
Steven PacelliExecutive VP of Strategy and Corporate Devel.Profile
Christine PospisilDirector EducationProfile
Shelly SelvarajSenior OfficerProfile
Leverne MarshExecutive MarketingProfile
Matthew DolanExecutive DevelopmentProfile
Teri LawverExecutive OfficerProfile
Donald AbbeyQuality ServicesProfile
Jereme SylvainCFO VPProfile
Paul FlynnEx RevenueProfile
Keri LeoneSenior EducationProfile
Barry ReganExecutive OperationsProfile
Jon ColemanExecutive OfficerProfile
Michael BrownExecutive OfficerProfile
Stacey StewartSenior OfficerProfile
Sadie SternExecutive OfficerProfile
Sean ChristensenDirector RelationsProfile

About DexCom Management Performance

The success or failure of an entity such as DexCom Inc often depends on how effective the management is. DexCom management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of DexCom management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the DexCom management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.09  0.10 
Return On Capital Employed 0.17  0.18 
Return On Assets 0.09  0.09 
Return On Equity 0.27  0.29 

DexCom Workforce Analysis

Traditionally, organizations such as DexCom use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare DexCom within its industry.

DexCom Manpower Efficiency

Return on DexCom Manpower

Revenue Per Employee395.4K
Revenue Per Executive192M
Net Income Per Employee56.5K
Net Income Per Executive27.4M
Working Capital Per Employee134.3K
Working Capital Per Executive65.2M
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.26)
Earnings Share
1.33
Revenue Per Share
10.533
Quarterly Revenue Growth
0.125
Return On Assets
0.0598
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.